Jeffrey Cohen, MD
Dermatology · New Haven, CTNPI 1689054397
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,641 of the $18,162 with a category attached, or 86.1%. Takeda Pharmaceuticals U.S.A., Inc. accounts for 61.3% of it on its own, with 9 other manufacturers making up the rest. Reporting peaked in 2024 at $12,160 and has fallen 67.2% since, to $3,984 in 2025.
Across 36 payments — averaging $504.51 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Takeda Pharmaceuticals U.S.A., Inc.$11K
- Sanofi$4K
- Novartis$2K
- GSK$817
- Regeneron Healthcare Solutions, Inc.$195
- Amgen$81
- plus $201 from 4 others
What the payments were for
- Consulting fees$15,64186%
- Travel & lodging$1,1837%
- Food & beverage$1,2307%
- Education$1091%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $11,132 |
| Sanofi | 10 | $4,087 |
| Novartis | 2 | $1,650 |
| GSK | 2 | $817 |
| Regeneron Healthcare Solutions, Inc. | 2 | $195 |
| Amgen | 4 | $81 |
| AbbVie | 2 | $79 |
| Almirall LLC | 1 | $57 |
| Abbott | 1 | $51 |
| Dermavant Sciences, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$3,829
How this compares
$18,162 in reported general payments places this provider in the 85th percentile of 222 dermatology providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 81 | $1,755,365 |
| Dupixent PenDupilumab | 278 | $1,420,599 |
| Humira(Cf) PenAdalimumab | 48 | $669,236 |
| TremfyaGuselkumab | 28 | $369,020 |
| OtezlaApremilast | 73 | $351,615 |
| Bimzelx AutoinjectorBimekizumab-Bkzx | 21 | $307,659 |
| Taltz AutoinjectorIxekizumab | 28 | $244,859 |
| Dupixent SyringeDupilumab | 38 | $216,138 |
| StelaraUstekinumab | 14 | $182,243 |
| RinvoqUpadacitinib | 13 | $81,989 |
| Adalimumab-Adaz(Cf) PenAdalimumab-Adaz | 16 | $39,035 |
| OpzeluraRuxolitinib Phosphate | 16 | $31,710 |
| JubliaEfinaconazole | 16 | $21,663 |
| VtamaTapinarof | 13 | $18,952 |
| ZoryveRoflumilast | 20 | $17,424 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenOtezla | $81 | $351,61573 claims |
| AbbVieRinvoq | $79 | $81,98913 claims |
| Dermavant Sciences, Inc.Vtama | $14 | $18,95213 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 222 dermatology providers in Connecticut.
Other dermatology in New Haven
- Christopher BunickNew Haven$661K
- Keith ChoateNew Haven$362K
- David LeffellNew Haven$94K
- Mariam TotonchyNew Haven$52K
- Lisa DonofrioNew Haven$38K
- Richard AntayaNew Haven$37K
- Leonard MilstoneNew Haven$31K
- William DamskyNew Haven$23K
- Michael GirardiNew Haven$20K
- Mary TomaykoNew Haven$13K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.